EGFR-Binding Peptides: From Computational Design towards Tumor-Targeting of Adeno-Associated Virus Capsids.
Rebecca C FeinerIsabell KemkerLea KrutzkeEllen AllmendingerDaniel J MandellNorbert SewaldStefan KochanekKristian M MüllerPublished in: International journal of molecular sciences (2020)
The epidermal growth factor receptor (EGFR) plays a central role in the progression of many solid tumors. We used this validated target to analyze the de novo design of EGFR-binding peptides and their application for the delivery of complex payloads via rational design of a viral vector. Peptides were computationally designed to interact with the EGFR dimerization interface. Two new peptides and a reference (EDA peptide) were chemically synthesized, and their binding ability characterized. Presentation of these peptides in each of the 60 capsid proteins of recombinant adeno-associated viruses (rAAV) via a genetic based loop insertion enabled targeting of EGFR overexpressing tumor cell lines. Furthermore, tissue distribution and tumor xenograft specificity were analyzed with systemic injection in chicken egg chorioallantoic membrane (CAM) assays. Complex correlations between the targeting of the synthetic peptides and the viral vectors to cells and in ovo were observed. Overall, these data demonstrate the potential of computational design in combination with rational capsid modification for viral vector targeting opening new avenues for viral vector delivery and specifically suicide gene therapy.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- gene therapy
- small cell lung cancer
- advanced non small cell lung cancer
- sars cov
- cancer therapy
- amino acid
- machine learning
- induced apoptosis
- risk assessment
- binding protein
- dna binding
- transcription factor
- gene expression
- drug delivery
- oxidative stress
- electronic health record
- high throughput
- genome wide
- artificial intelligence
- cell cycle arrest
- signaling pathway
- drug induced
- big data
- data analysis